1
|
Chen S, Zhao Y, Yang Z, Li Y, Shi H, Zhao T, Yang X, Li J, Li G, Wang J, Ying Z, Yang J. The impact of different IPV-OPV sequential immunization programs on hepatitis A and hepatitis B vaccine efficacy. Hum Vaccin Immunother 2022; 18:2024063. [PMID: 35044877 PMCID: PMC8993082 DOI: 10.1080/21645515.2021.2024063] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022] Open
Abstract
In recent years, the Global Polio Eradication Initiative has gradually implemented a global shift in polio immunization programs. Few studies cover polio immunization program impacts on the efficacy of other vaccines. This study investigated whether polio immunization programs affected hepatitis A (HepA) and hepatitis B (HepB) vaccination efficacy. Serum samples were collected from 968 infants before the first dose of polio vaccine, 28 days after completing primary polio immunization, and at 24 months old. Infants were classified into six polio immunization program groups: 1sIPV+2bOPV, 2sIPV+1bOPV, 2sIPV+1tOPV, 1cIPV+2bOPV, 2cIPV+1bOPV, and 2cIPV+1tOPV (sIPV: Sabin inactivated poliovirus vaccine; cIPV: Salk inactivated poliovirus vaccine; b, bivalent; t, trivalent; OPV, oral polio vaccine). No significant differences existed in antibody titers against HepA virus (anti-HAV) among the polio immunization program groups at any of the three time points (pre-first dose [p = 0.412], 28 days after primary immunization [p = 0.676], 24 months old [p = 0.556]). Before the first dose (p = 0.178) and at age 24 months (p = 0.987), no significant differences existed in HepB surface antibody (HBsAb) titers between the six polio immunization program groups). Twenty-eight days after primary immunization, no significant difference existed in HBsAb titers between groups after Bonferroni correction. Following HepA and HepB immunization, anti-HAV and HBsAb positivity reached > 98% in all groups, reflecting effective immunization. Our data suggest that different polio immunization programs did not affect HepA and HepB vaccine efficacy; HepA and HepB vaccines maintained high effectiveness irrespective of polio immunization program. This trial was registered on Clinical Trials.gov: NCT03614702.
Collapse
Affiliation(s)
- Shiyi Chen
- Institute of Medical Biology, Chinese Academy of Medical Sciences, Peking Union Medical College, Kunming, China
| | - Yuping Zhao
- Institute of Medical Biology, Chinese Academy of Medical Sciences, Peking Union Medical College, Kunming, China
| | - Zhiyao Yang
- Faculty of Science, The University of Adelaide, Adelaide, Australia
| | - Ying Li
- Institute of Medical Biology, Chinese Academy of Medical Sciences, Peking Union Medical College, Kunming, China
| | - Hongyuan Shi
- Institute of Medical Biology, Chinese Academy of Medical Sciences, Peking Union Medical College, Kunming, China
| | - Ting Zhao
- Institute of Medical Biology, Chinese Academy of Medical Sciences, Peking Union Medical College, Kunming, China.,National Local Joint Engineering Research Center for Biological Products of Viral Infectious Diseases
| | - Xiaolei Yang
- Institute of Medical Biology, Chinese Academy of Medical Sciences, Peking Union Medical College, Kunming, China.,National Local Joint Engineering Research Center for Biological Products of Viral Infectious Diseases
| | - Jing Li
- Institute of Medical Biology, Chinese Academy of Medical Sciences, Peking Union Medical College, Kunming, China.,National Local Joint Engineering Research Center for Biological Products of Viral Infectious Diseases
| | - Guoliang Li
- Institute of Medical Biology, Chinese Academy of Medical Sciences, Peking Union Medical College, Kunming, China.,National Local Joint Engineering Research Center for Biological Products of Viral Infectious Diseases
| | - Jianfeng Wang
- Laboratory of respiratory virus vaccine, National Institutes for Food and Drug Control, Beijing, China
| | - Zhifang Ying
- Laboratory of respiratory virus vaccine, National Institutes for Food and Drug Control, Beijing, China
| | - Jingsi Yang
- Institute of Medical Biology, Chinese Academy of Medical Sciences, Peking Union Medical College, Kunming, China.,National Local Joint Engineering Research Center for Biological Products of Viral Infectious Diseases
| |
Collapse
|
2
|
Agrawal A, Singh S, Kolhapure S, Hoet B, Arankalle V, Mitra M. Increasing Burden of Hepatitis A in Adolescents and Adults and the Need for Long-Term Protection: A Review from the Indian Subcontinent. Infect Dis Ther 2019; 8:483-497. [PMID: 31679118 PMCID: PMC6856242 DOI: 10.1007/s40121-019-00270-9] [Citation(s) in RCA: 24] [Impact Index Per Article: 4.8] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/12/2019] [Indexed: 02/06/2023] Open
Abstract
Hepatitis A, an acute inflammatory liver disease caused by hepatitis A virus (HAV) infection from close contact with infected people, is highly endemic in the Indian subcontinent. Due to poor sanitary conditions, most of the population is exposed to the virus in childhood. At this age, the disease is asymptomatic and provides life-long protection against the disease. Due to rapid socioeconomic development in some areas, however, pockets of the population are reaching adolescence/adulthood without prior exposure to the virus and are thus susceptible to infection. At these ages, infection carries a higher risk of symptomatic disease and complications including mortality. This review of epidemiology and burden of disease studies in the Indian subcontinent, published since 2005, shows increasing evidence of a shift from high to intermediate endemicity in high-income-typically urban-populations. The prevalence of anti-HAV antibodies (previously reported at > 90%) is lower now in adolescents and young adults (e.g., around 80% in Bangladesh and 55% in 5-15 years in India). As a result, HAV is responsible for more acute viral hepatitis predominantly in this age group (e.g., > 15 years: 3.4% in 1999 to 12.3% in 2003 or high socioeconomic status 13-20 years: 27% in 1999 to 62% in 2003), with a greater clinical and economic burden. Numerous outbreaks due to HAV have been reported [e.g., Sri Lanka (2009-2010): > 13,000 affected; Kashmir (2015-2017): 12 outbreaks; Kerala (2012-2016): 84 outbreaks] from water or food contamination. Due to current shifts in endemicity, a growing proportion of the population is no longer exposed in childhood. As the disease remains highly endemic, it also provides a source for more severe disease in susceptible people at an older age and for outbreaks. Well-tolerated and effective vaccines are available and help prevent disease burden and provide long-term protection. These should now be used more widely to protect more patients from the growing disease burden of hepatitis A. FUNDING: GlaxoSmithKline Biologicals SA. Plain language summary available for this article-please see Fig. 1 and the following link: https://doi.org/10.6084/m9.figshare.9963044.Fig. 1Plain Language Summary. Highlights the context of the article, the endemicity shift and the burden of hepatitis A in adolescents and adults and steps to be taken to address the impact of this disease.
Collapse
|
3
|
Abstract
Worldwide, there are multiple formaldehyde-inactivated and at least two live attenuated hepatitis A vaccines now in clinical use. The impressive immunogenicity of inactivated vaccines is reflected in rapid seroconversion rates, enabling both preexposure and postexposure prophylaxis. Universal childhood vaccination programs targeting young children have led to significant drops in the incidence of hepatitis A both in toddlers and in susceptible nonimmune adults in regions with intermediate endemicity for hepatitis A. Although the safety of inactivated vaccines is well established, further studies are needed concerning the implications of fecal virus shedding by recipients of attenuated vaccines, as well as the long-term persistence of immune memory in children receiving novel immunization schedules consisting of single doses of inactivated vaccines.
Collapse
Affiliation(s)
- Daniel Shouval
- Liver Unit, Institute for Gastroenterology and Hepatology, Hadassah-Hebrew University Hospital, Jerusalem 91120, Israel
| |
Collapse
|
4
|
Luo J, Wang X, Ma F, Kang G, Ding Z, Ye C, Pan Y, Zhao Y, Hong S, Chen J, Xi J, Wen S, Lin Y, Li X, Qiu L, Yang X, Li G, Yang J, Sun Q. Long-term immunogenicity and immune persistence of live attenuated and inactivated hepatitis a vaccines: a report on additional observations from a phase IV study. Clin Microbiol Infect 2018; 25:1422-1427. [PMID: 30496870 DOI: 10.1016/j.cmi.2018.11.005] [Citation(s) in RCA: 8] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/19/2018] [Revised: 10/24/2018] [Accepted: 11/03/2018] [Indexed: 12/20/2022]
Abstract
Both live attenuated (HA-L) and inactivated (HA-I) hepatitis A vaccine were licensed for routine use in China. Although phase 1, 2 and 3 clinical studies of both vaccines have been completed, further systematic evaluation of their immunogenicity and immunological persistence under phase 4 clinical studies in a wide range of conditions and involving large populations is necessary. A phase IV clinical trial (NCT02601040) was performed in 9000 participants over 18 months of age. Geometric mean concentrations (GMCs) and seroconversion rates (SRs) were compared at five time points during 3 years for 1800 individuals among them. The SRs of HA-L and HA-I were 98.08% (95% CI 95.59%-99.38%) and 99.64% (95% CI 98.93%-100.00%) respectively 28 days after administration of the first dose, and remained at 97.07% (95% CI 94.31%-98.73%) or above and 96.73% (95% CI 94.07%-98.42%) or above respectively during the following 3 years. The GMCs for both the HA-L and HA-I groups showed that both vaccines elicited high anti-HAV titres, considerably more than the threshold of protection needed against HAV infection in humans, and these titres were sustained. Hence, both HA-I and HA-L vaccines could provide an excellent long-term protective effect, and supported the routine use of both vaccines.
Collapse
Affiliation(s)
- J Luo
- Institute of Medical Biology, Chinese Academy of Medical Sciences, Peking Union Medical College, Kunming, China; Yunnan Key Laboratory of Vaccine Research and Development on Severe Infectious Diseases, Kunming, China; Yunnan Provincial Key Laboratory of Vector-borne Diseases Control and Research, Kunming, China; Kunming Medical University Haiyuan College, Kunming, China
| | - X Wang
- Institute of Medical Biology, Chinese Academy of Medical Sciences, Peking Union Medical College, Kunming, China; Yunnan Key Laboratory of Vaccine Research and Development on Severe Infectious Diseases, Kunming, China; Yunnan Provincial Key Laboratory of Vector-borne Diseases Control and Research, Kunming, China
| | - F Ma
- Jiangsu Provincial Centre of Disease Control and Prevention, Nanjing, China
| | - G Kang
- Jiangsu Provincial Centre of Disease Control and Prevention, Nanjing, China
| | - Z Ding
- Yunnan Provincial Centre of Disease Control and Prevention, Kunming, Yunnan Province, China
| | - C Ye
- Institute of Medical Biology, Chinese Academy of Medical Sciences, Peking Union Medical College, Kunming, China; Yunnan Key Laboratory of Vaccine Research and Development on Severe Infectious Diseases, Kunming, China; Yunnan Provincial Key Laboratory of Vector-borne Diseases Control and Research, Kunming, China; Kunming Medical University, Kunming, China
| | - Y Pan
- Institute of Medical Biology, Chinese Academy of Medical Sciences, Peking Union Medical College, Kunming, China; Yunnan Key Laboratory of Vaccine Research and Development on Severe Infectious Diseases, Kunming, China; Yunnan Provincial Key Laboratory of Vector-borne Diseases Control and Research, Kunming, China
| | - Y Zhao
- Institute of Medical Biology, Chinese Academy of Medical Sciences, Peking Union Medical College, Kunming, China; Yunnan Key Laboratory of Vaccine Research and Development on Severe Infectious Diseases, Kunming, China; Yunnan Provincial Key Laboratory of Vector-borne Diseases Control and Research, Kunming, China
| | - S Hong
- Institute of Medical Biology, Chinese Academy of Medical Sciences, Peking Union Medical College, Kunming, China; Yunnan Key Laboratory of Vaccine Research and Development on Severe Infectious Diseases, Kunming, China; Yunnan Provincial Key Laboratory of Vector-borne Diseases Control and Research, Kunming, China; Kunming Medical University, Kunming, China
| | - J Chen
- Institute of Medical Biology, Chinese Academy of Medical Sciences, Peking Union Medical College, Kunming, China; Yunnan Key Laboratory of Vaccine Research and Development on Severe Infectious Diseases, Kunming, China; Yunnan Provincial Key Laboratory of Vector-borne Diseases Control and Research, Kunming, China
| | - J Xi
- Institute of Medical Biology, Chinese Academy of Medical Sciences, Peking Union Medical College, Kunming, China; Yunnan Key Laboratory of Vaccine Research and Development on Severe Infectious Diseases, Kunming, China; Yunnan Provincial Key Laboratory of Vector-borne Diseases Control and Research, Kunming, China
| | - S Wen
- Institute of Medical Biology, Chinese Academy of Medical Sciences, Peking Union Medical College, Kunming, China; Yunnan Key Laboratory of Vaccine Research and Development on Severe Infectious Diseases, Kunming, China; Yunnan Provincial Key Laboratory of Vector-borne Diseases Control and Research, Kunming, China
| | - Y Lin
- Institute of Medical Biology, Chinese Academy of Medical Sciences, Peking Union Medical College, Kunming, China; Yunnan Key Laboratory of Vaccine Research and Development on Severe Infectious Diseases, Kunming, China; Yunnan Provincial Key Laboratory of Vector-borne Diseases Control and Research, Kunming, China
| | - X Li
- The Affiliated Children's Hospital of Kunming Medical University, Kunming, China
| | - L Qiu
- Institute of Medical Biology, Chinese Academy of Medical Sciences, Peking Union Medical College, Kunming, China; The Affiliated Children's Hospital of Kunming Medical University, Kunming, China
| | - X Yang
- Institute of Medical Biology, Chinese Academy of Medical Sciences, Peking Union Medical College, Kunming, China; Yunnan Key Laboratory of Vaccine Research and Development on Severe Infectious Diseases, Kunming, China; Yunnan Provincial Key Laboratory of Vector-borne Diseases Control and Research, Kunming, China
| | - G Li
- Institute of Medical Biology, Chinese Academy of Medical Sciences, Peking Union Medical College, Kunming, China; Yunnan Key Laboratory of Vaccine Research and Development on Severe Infectious Diseases, Kunming, China; Yunnan Provincial Key Laboratory of Vector-borne Diseases Control and Research, Kunming, China
| | - J Yang
- Institute of Medical Biology, Chinese Academy of Medical Sciences, Peking Union Medical College, Kunming, China; Yunnan Key Laboratory of Vaccine Research and Development on Severe Infectious Diseases, Kunming, China; Yunnan Provincial Key Laboratory of Vector-borne Diseases Control and Research, Kunming, China.
| | - Q Sun
- Institute of Medical Biology, Chinese Academy of Medical Sciences, Peking Union Medical College, Kunming, China; Yunnan Key Laboratory of Vaccine Research and Development on Severe Infectious Diseases, Kunming, China; Yunnan Provincial Key Laboratory of Vector-borne Diseases Control and Research, Kunming, China.
| |
Collapse
|
5
|
Rao S, Mao JS, Motlekar S, Fangcheng Z, Kadhe G. A review of immunogenicity and tolerability of live attenuated Hepatitis A vaccine in children. Hum Vaccin Immunother 2017; 12:3160-3165. [PMID: 27532370 PMCID: PMC5215502 DOI: 10.1080/21645515.2016.1216286] [Citation(s) in RCA: 16] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/05/2023] Open
Abstract
Changing epidemiology of Hepatitis A virus (HAV) has led to an increased susceptibility of adolescents and adults to the infection. Vaccination can remarkably reduce the incidence and associated morbidity of HAV infection. This review is focused on the safety and efficacy of H2 strain derived live attenuated Hepatitis A vaccine. We found the vaccine to be highly immunogenic with minimal or negligible safety issues. Moreover, a single dose of live attenuated vaccine persists a long term immune response and can be a preferred option for developing countries. In 2014, Indian Academy of Paediatrics (IAP) also updated their recommendations for H2 vaccine as a single dose as against the previous 2 dose schedule. A focused approach to include the vaccine in national immunization program should be explored.
Collapse
Affiliation(s)
- Sameer Rao
- a Medical Affairs Department , Wockhardt Ltd , Bandra (East), Mumbai , India
| | - J S Mao
- b Institute of Viral Diseases, Zhejiang Academy of Medical Sciences , Hangzhou , China
| | - Salman Motlekar
- a Medical Affairs Department , Wockhardt Ltd , Bandra (East), Mumbai , India
| | - Zhuang Fangcheng
- b Institute of Viral Diseases, Zhejiang Academy of Medical Sciences , Hangzhou , China
| | - Ganesh Kadhe
- a Medical Affairs Department , Wockhardt Ltd , Bandra (East), Mumbai , India
| |
Collapse
|
6
|
Zhang Z, Zhu X, Hu Y, Liang M, Sun J, Song Y, Yang Q, Ji H, Zeng G, Song L, Chen J. Five-year antibody persistence in children after one dose of inactivated or live attenuated hepatitis A vaccine. Hum Vaccin Immunother 2017; 13:1-6. [PMID: 28319454 DOI: 10.1080/21645515.2016.1278329] [Citation(s) in RCA: 9] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/20/2022] Open
Abstract
In China, both inactivated hepatitis A (HA) vaccine and live attenuated HA vaccine are available. We conducted a trial to evaluate 5-year immune persistence induced by one dose of inactivated or live attenuated HA vaccines in children. Subjects with no HA vaccination history had randomly received one dose of inactivated or live attenuated HA vaccine at 18-60 months of age. Anti-HAV antibody concentrations were measured before vaccination and at the first, second, and fifth year after vaccination. Suspected cases of hepatitis A were monitored during the study period. A total of 332 subjects were enrolled and 182 provided evaluable serum samples at all planned time points. seropositive rate at 5 y was 85.9% in the inactivated HA vaccine group and 90.7% in the live attenuated HA vaccine group. GMCs were 76.3% mIU/ml (95% CI: 61.7 - 94.4) and 66.8mIU/ml (95% CI: 57.8 - 77.3), respectively. No significant difference in antibody persistence between 2 groups was found. No clinical hepatitis A case was reported. A single dose of an inactivated or live attenuated HA vaccine at 18-60 months of age resulted in high HAV seropositive rate and anti-HAV antibody concentrations that lasted for at least 5 y.
Collapse
Affiliation(s)
- Zhilun Zhang
- a Tianjin Center for Disease Control and Prevention , Tianjin , China
| | - Xiangjun Zhu
- a Tianjin Center for Disease Control and Prevention , Tianjin , China
| | | | - Miao Liang
- a Tianjin Center for Disease Control and Prevention , Tianjin , China
| | - Jin Sun
- a Tianjin Center for Disease Control and Prevention , Tianjin , China
| | - Yufei Song
- b Sinovac Biotech Co., LTD. , Beijing , China
| | - Qi Yang
- c Jixian county Center for Disease Control and Prevention , Jixian, Tianjin , China
| | - Haiquan Ji
- c Jixian county Center for Disease Control and Prevention , Jixian, Tianjin , China
| | - Gang Zeng
- b Sinovac Biotech Co., LTD. , Beijing , China
| | - Lifei Song
- b Sinovac Biotech Co., LTD. , Beijing , China
| | | |
Collapse
|
7
|
Zhang X, An J, Tu A, Liang X, Cui F, Zheng H, Tang Y, Liu J, Wang X, Zhang N, Li H. Comparison of immune persistence among inactivated and live attenuated hepatitis a vaccines 2 years after a single dose. Hum Vaccin Immunother 2016; 12:2322-6. [PMID: 27494260 PMCID: PMC5027719 DOI: 10.1080/21645515.2015.1134069] [Citation(s) in RCA: 9] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/15/2015] [Revised: 12/02/2015] [Accepted: 12/16/2015] [Indexed: 01/11/2023] Open
Abstract
OBJECTIVE Compare immune persistence from one dose of each of 3 different hepatitis A vaccines when given to school-age children: a domestic, live attenuated hepatitis A vaccine (H2 vaccine); a domestic inactivated hepatitis A vaccine (Healive®); and an imported, inactivated hepatitis A vaccine (Havrix®),. METHODS School-age children were randomized into 1 of 4 groups to receive a single dose of a vaccine: H2 vaccine, Healive®, Havrix®, or hepatitis B vaccine [control]. Serum samples were collected 12 and 24 months after vaccination for measurement of anti-HAV IgG using microparticle enzyme immunoassay. Seropositivity was defined as ≥ 20 mUI/ml. We compared groups on seropositivity and geometric mean concentration (GMC). RESULTS Seropositive rates for the H2, Healive®, Havrix®, and control groups were 64%, 94.4%, 73%, and 1.0%, respectively, 12-months post-vaccination; and 63%, 95.6%, 72%, and 1.0%, respectively 24-months post-vaccination. Seropositivity was greater for Healive® than for H2 and Havrix® at 12 months (p-values < 0.001) and 24 months (p-values < 0.0001). Average GMCs for the H2, Healive®, Havrix®, and control groups, in mIU/ml, were 29.7, 81.0, 36.4, and 2.9, respectively at 12 months, and 30.9, 112.2, 44.3, and 2.9, respectively, at 24 months. GMCs were greater for Healive® than for H2 and Havrix® at 12 months (p-values < 0.0001 and < 0.001, respectively) and 24 months (p-values < 0.001). No statistically significant differences in seropositivity or GMC were found within groups between 12 and 24 months. CONCLUSION Immunity persisted 24 months after a single dose of inactivated hepatitis A vaccine and live attenuated hepatitis A vaccine.
Collapse
Affiliation(s)
- Xiaoshu Zhang
- GanSu Provincial Center for Disease Control and Prevention, Lanzhou, China
| | - Jing An
- GanSu Provincial Center for Disease Control and Prevention, Lanzhou, China
| | - Aixia Tu
- GanSu Provincial Center for Disease Control and Prevention, Lanzhou, China
| | - Xuefeng Liang
- GanSu Provincial Center for Disease Control and Prevention, Lanzhou, China
| | - Fuqiang Cui
- Chinese Center for Disease Control and Prevention, Beijing, China
| | - Hui Zheng
- Chinese Center for Disease Control and Prevention, Beijing, China
| | - Yu Tang
- GanSu Provincial Center for Disease Control and Prevention, Lanzhou, China
| | - Jianfeng Liu
- GanSu Provincial Center for Disease Control and Prevention, Lanzhou, China
| | - Xuxia Wang
- GanSu Provincial Center for Disease Control and Prevention, Lanzhou, China
| | - Ningjing Zhang
- GanSu Provincial Center for Disease Control and Prevention, Lanzhou, China
| | - Hui Li
- GanSu Provincial Center for Disease Control and Prevention, Lanzhou, China
| |
Collapse
|
8
|
Ma F, Yang J, Kang G, Sun Q, Lu P, Zhao Y, Wang Z, Luo J, Wang Z. Comparison of the safety and immunogenicity of live attenuated and inactivated hepatitis A vaccine in healthy Chinese children aged 18 months to 16 years: results from a randomized, parallel controlled, phase IV study. Clin Microbiol Infect 2016; 22:811.e9-811.e15. [PMID: 27345175 DOI: 10.1016/j.cmi.2016.06.004] [Citation(s) in RCA: 8] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/26/2016] [Revised: 06/10/2016] [Accepted: 06/11/2016] [Indexed: 11/25/2022]
Abstract
For large-scale immunization of children with hepatitis A (HA) vaccines in China, accurately designed studies comparing the safety and immunogenicity of the live attenuated HA vaccine (HA-L) and inactivated HA vaccine (HA-I) are necessary. A randomized, parallel controlled, phase IV clinical trial was conducted with 6000 healthy children aged 18 months to 16 years. HA-L or HA-I was administered at a ratio of 1: 1 to randomized selected participants. The safety and immunogenicity were evaluated. Both HA-L and HA-I were well tolerated by all participants. The immunogenicity results showed that the seroconversion rates (HA-L versus HA-I: 98.0% versus 100%, respectively, p >0.05), and geometric mean concentrations in participants negative for antibodies against HA virus IgG (anti-HAV IgG) before vaccination did not differ significantly between the two types of vaccines (HA-L versus HA-I first dose: 898.9 versus 886.2 mIU/mL, respectively, p >0.05). After administration of the booster dose of HA-I, the geometric mean concentrations of anti-HAV IgG (HA-I booster dose: 2591.2 mIU/mL) was higher than that after the first dose (p <0.05) and that reported in participants administered HA-L (p <0.05). Additionally, 12 (25%) of the 48 randomized selected participants who received HA-L tested positive for HA antigen in stool samples. Hence, both HA-L and HA-I could provide acceptable immunogenicity in children. The effects of long-term immunogenicity after natural exposure to wild-type HA virus and the possibility of mutational shifts of the live vaccine virus in the field need to be studied in more detail.
Collapse
Affiliation(s)
- F Ma
- Jiangsu Provincial Centre of Disease Control and Prevention, Nanjing, Jiangsu Province, China
| | - J Yang
- Institute of Medical Biology, Chinese Academy of Medical Sciences, Kunming, Yunnan Province, China
| | - G Kang
- Jiangsu Provincial Centre of Disease Control and Prevention, Nanjing, Jiangsu Province, China.
| | - Q Sun
- Institute of Medical Biology, Chinese Academy of Medical Sciences, Kunming, Yunnan Province, China
| | - P Lu
- Jiangsu Provincial Centre of Disease Control and Prevention, Nanjing, Jiangsu Province, China
| | - Y Zhao
- Institute of Medical Biology, Chinese Academy of Medical Sciences, Kunming, Yunnan Province, China
| | - Z Wang
- Jiangsu Provincial Centre of Disease Control and Prevention, Nanjing, Jiangsu Province, China
| | - J Luo
- Institute of Medical Biology, Chinese Academy of Medical Sciences, Kunming, Yunnan Province, China
| | - Z Wang
- Xiangshui County Centre of Disease Control and Prevention, Jiangsu Province, China
| |
Collapse
|
9
|
Liu XE, Chen HY, Liao Z, Zhou Y, Wen H, Peng S, Liu Y, Li R, Li J, Zhuang H. Comparison of Immunogenicity Between Inactivated and Live Attenuated Hepatitis A Vaccines Among Young Adults: A 3-Year Follow-up Study. J Infect Dis 2015; 212:1232-6. [PMID: 25969561 DOI: 10.1093/infdis/jiv213] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/23/2014] [Accepted: 03/30/2015] [Indexed: 11/13/2022] Open
Abstract
UNLABELLED A randomized clinical trial of hepatitis A vaccines (1 or 2 doses of inactivated vaccine [Healive] or 1 dose of live attenuated vaccine [Biovac]) was conducted among adults to evaluate seroprotection rates and geometric mean concentrations of antibody against hepatitis A virus for 36 months. High rates of seroprotection persisted for at least 36 months among adults who received 1 or 2 doses of inactivated hepatitis A vaccine but not among adults who received 1 dose of live attenuated hepatitis A vaccine. The long-term serial monitoring of immunogenicity induced by 1 dose of inactivated hepatitis A vaccine is needed to determine an effective alternative to a 2-dose schedule. CLINICAL TRIALS REGISTRATION NCT01865968.
Collapse
Affiliation(s)
- Xue-en Liu
- Department of Microbiology and Center of Infectious Disease, School of Basic Medical Sciences, Peking University Health Science Center, Beijing
| | - Hai-ying Chen
- Nanchang Center for Disease Control and Prevention, Jiangxi
| | - Zheng Liao
- Nanchang Center for Disease Control and Prevention, Jiangxi
| | - Yisheng Zhou
- Nanchang Center for Disease Control and Prevention, Jiangxi
| | - Hairong Wen
- Nanchang Center for Disease Control and Prevention, Jiangxi
| | - Shihui Peng
- Nanchang Center for Disease Control and Prevention, Jiangxi
| | - Yan Liu
- Sinovac Biotech, Beijing, China
| | - Rui Li
- Department of Microbiology and Center of Infectious Disease, School of Basic Medical Sciences, Peking University Health Science Center, Beijing
| | - Jie Li
- Department of Microbiology and Center of Infectious Disease, School of Basic Medical Sciences, Peking University Health Science Center, Beijing
| | - Hui Zhuang
- Department of Microbiology and Center of Infectious Disease, School of Basic Medical Sciences, Peking University Health Science Center, Beijing
| |
Collapse
|